Published in Arterioscler Thromb Vasc Biol on December 03, 2009
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol (2011) 2.60
HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun (2014) 1.40
5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther (2010) 1.34
Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. Circ Res (2010) 1.14
5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol (2010) 1.13
Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. Pharmacol Ther (2010) 1.12
Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev (2012) 1.11
Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol (2012) 1.07
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol (2010) 1.06
Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis. J Inflamm Res (2011) 1.00
HDL and endothelial protection. Br J Pharmacol (2013) 0.99
Ginsenoside-Rp1-induced apolipoprotein A-1 expression in the LoVo human colon cancer cell line. J Ginseng Res (2014) 0.95
Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. J Lipid Res (2014) 0.92
Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. Vasc Health Risk Manag (2014) 0.92
A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice. J Pharmacol Exp Ther (2014) 0.90
Apolipoprotein mimetic peptides: a new approach for the treatment of asthma. Front Pharmacol (2012) 0.89
HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders. Curr Pharm Des (2010) 0.87
HDL, Atherosclerosis, and Emerging Therapies. Cholesterol (2013) 0.87
The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties. J Lipid Res (2015) 0.87
Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity. J Biol Chem (2012) 0.86
New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma. Chest (2011) 0.86
Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties. Arterioscler Thromb Vasc Biol (2015) 0.80
Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter. J Pharmacol Exp Ther (2012) 0.78
New Era of Lipid-Lowering Drugs. Pharmacol Rev (2016) 0.77
The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit. Lipids Health Dis (2011) 0.77
High-density lipoprotein mimetics: promises and challenges. Biochem J (2015) 0.76
Intriguing bronchoalveolar lavage proteome in a case of pulmonary langerhans cell histiocytosis. Am J Case Rep (2013) 0.75
Identification of a novel lipid binding motif in apolipoprotein B by the analysis of hydrophobic cluster domains. Biochim Biophys Acta (2016) 0.75
The 5A apolipoprotein A-I (apoA-I) mimetic peptide ameliorates experimental colitis by regulating monocyte infiltration. Br J Pharmacol (2016) 0.75
High-density lipoprotein: a novel target for antirestenosis therapy. Clin Transl Sci (2014) 0.75
The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease. Front Pharmacol (2017) 0.75
Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA Clin (2017) 0.75
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55
New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res (2005) 4.47
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA (2007) 3.12
Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J (2008) 3.04
NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal (2006) 2.95
Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem (2008) 2.87
Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation (2004) 2.62
Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem (1982) 2.36
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res (2008) 2.27
Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med (2008) 2.15
Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res (2001) 2.11
Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem (2001) 1.92
Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res (2003) 1.68
Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res (2007) 1.65
Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation (2005) 1.53
L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation (2003) 1.53
High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) (2009) 1.43
Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem (2008) 1.41
HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther (2008) 1.30
HO-2 provides endogenous protection against oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am J Physiol Cell Physiol (2006) 1.25
Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs (2007) 1.24
TNF-alpha potentiates protein-tyrosine nitration through activation of NADPH oxidase and eNOS localized in membrane rafts and caveolae of bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol (2006) 1.24
Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol (2006) 1.21
Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis (2007) 1.05
Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res (2005) 1.03
Endothelial cell oxidative stress and signal transduction. Biol Res (2000) 1.02
The protective effects of HDL and its constituents against neutrophil respiratory burst activation by hypochlorite-oxidized LDL. Mol Cell Biochem (2004) 0.82
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol (2011) 8.21
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res (2009) 6.83
Antiinflammatory properties of HDL. Circ Res (2004) 5.41
Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA (2008) 4.41
Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.92
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol (2008) 3.09
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest (2003) 3.09
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation (2011) 3.01
ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol (2005) 2.46
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med (2007) 2.41
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem (2011) 2.33
MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology (2012) 2.15
Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity (Silver Spring) (2009) 2.07
Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem (2010) 2.07
Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem (2003) 2.04
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res (2006) 1.99
Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma. Am J Respir Crit Care Med (2015) 1.97
Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol (2003) 1.94
High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol (2006) 1.84
Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol (2006) 1.84
Chinese herbs Danshen and Gegen modulate key early atherogenic events in vitro. Int J Cardiol (2005) 1.83
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res (2005) 1.79
Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis (2010) 1.76
Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas. Gastroenterology (2007) 1.75
The metabolism and anti-atherogenic properties of HDL. J Lipid Res (2008) 1.74
Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol (2012) 1.73
Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med (Berl) (2008) 1.72
Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci U S A (2008) 1.71
Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance? Metabolism (2009) 1.69
Repetitive hypoxia increases lipid loading in human macrophages-a potentially atherogenic effect. Atherosclerosis (2005) 1.63
The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci U S A (2001) 1.61
Impact of blood collection devices on clinical chemistry assays. Clin Biochem (2009) 1.61
Class B scavenger receptor types I and II and CD36 targeting improves sepsis survival and acute outcomes in mice. J Immunol (2012) 1.61
What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol (2005) 1.61
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem (2006) 1.60
Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling. Hypertension (2009) 1.59
Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension (2010) 1.57
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem (2008) 1.56
Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X. Arterioscler Thromb Vasc Biol (2006) 1.56
Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem (2004) 1.55
Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol (2010) 1.55
Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation (2011) 1.55
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology (2015) 1.55
Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol (2009) 1.53
Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation (2005) 1.53
Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J Clin Invest (2011) 1.52
Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I. Cardiovasc Res (2011) 1.51
Role of human CD36 in bacterial recognition, phagocytosis, and pathogen-induced JNK-mediated signaling. J Immunol (2008) 1.51
The prevalence of hypovitaminosis D and secondary hyperparathyroidism in obese Black Americans. Clin Endocrinol (Oxf) (2006) 1.50
High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50
Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.50
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet (2015) 1.50
Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis (2011) 1.50
Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. J Mol Med (Berl) (2012) 1.48
Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clin Sci (Lond) (2006) 1.47
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res (2012) 1.46
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol (2011) 1.45
Effect of blood collection tubes on total triiodothyronine and other laboratory assays. Clin Chem (2004) 1.45
Immunoassay interference by a commonly used blood collection tube additive, the organosilicone surfactant silwet L-720. Clin Chem (2005) 1.44
The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J Biol Chem (2004) 1.44
High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) (2009) 1.43
Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo. Clin Endocrinol (Oxf) (2006) 1.42
Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem (2008) 1.41
Coronary plaque regression: role of low density lipoprotein-apheresis. J Am Coll Cardiol (2002) 1.41
Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect Immun (2002) 1.40
Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. J Biol Chem (2010) 1.40
Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer (2007) 1.38
Diverse range of small peptides associated with high-density lipoprotein. Biochem Biophys Res Commun (2005) 1.34
5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther (2010) 1.34
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol (2010) 1.33
Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol (2005) 1.32
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol (2007) 1.30
Cardioprotective functions of HDLs. J Lipid Res (2013) 1.29
Molecular basis of PCSK9 function. Atherosclerosis (2008) 1.29
Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes (2009) 1.29
Prevalence of HIV and hepatitis C virus infections among inmates of Quebec provincial prisons. CMAJ (2007) 1.27
Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Biol (2012) 1.27
New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep (2007) 1.26
Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs (2007) 1.24
Disruption of the Arnt gene in endothelial cells causes hepatic vascular defects and partial embryonic lethality in mice. Hepatology (2006) 1.24
δ-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders. J Biol Chem (2012) 1.23
ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis. J Biol Chem (2006) 1.23